Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Pfizer’s $10B monthly GLP-1 bet generates competitive weight loss in phase 2b (Fierce Biotech)
- ‘AI-native’ outpatient surgery startup Oath Surgical inks Nvidia partnership (Fierce Biotech)
- NVIDIA, Oath Surgical, ASCs and the Future of Physical AI in Healthcare (LSI | LinkedIn)
- UMass Successfully Performs Its First Full-Thickness Resection Device Procedure (UMass Chan Medical School)
- 5 gastroenterology physician moves in 1 month (Becker’s GI & Endoscopy)
- Artificial Intelligence on Trial: Who’s Liable When Clinical Algorithms Go Wrong? (Medscape)
- Building the Future Gastroenterologist: Why Nutrition and Lifestyle Medicine Must Be Core Competencies (ACG Case Reports Journal)
- Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett’s Esophagus and Esophageal Cancer Using a Modified Delphi Process (The American Journal of Gastroenterology)
